Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer

NCT00066690 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT00066690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00066690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 3
Overall status
Completed
Start date
December 17, 2003
Completion date
November 6, 2024
Enrollment
3,066 (actual)
Sites
500

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor positive breast cancer, progesterone receptor positive tumor, recurrent breast carcinoma, stage ia breast cancer, stage ib breast cancer, stage iia breast cancer, stage iib breast cancer, stage iiia breast cancer